Chordate Medical Receives Trademark Registration for Ozilia® in the United States
Kurs
+6,61%
Likviditet
0,08 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2025-05-23 | 08:30 | Kvartalsrapport 2025-Q1 |
| 2025-05-22 | N/A | X-dag ordinarie utdelning CMH 0.00 SEK |
| 2025-05-22 | N/A | X-dag ordinarie utdelning CMH PREF 0.00 SEK |
| 2025-05-21 | N/A | Årsstämma |
| 2025-03-28 | - | Bokslutskommuniké 2024 |
| 2025-01-28 | - | Extra Bolagsstämma 2025 |
| 2024-11-05 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-30 | - | Kvartalsrapport 2024-Q2 |
| 2024-08-29 | - | Split CMH 500:1 |
| 2024-05-24 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-20 | - | X-dag ordinarie utdelning CMH 0.00 SEK |
| 2024-05-15 | - | Årsstämma |
| 2024-03-22 | - | Bokslutskommuniké 2023 |
| 2024-01-26 | - | Extra Bolagsstämma 2024 |
| 2023-11-01 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-31 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | - | Kvartalsrapport 2023-Q1 |
| 2023-04-14 | - | X-dag ordinarie utdelning CMH 0.00 SEK |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2022-12-13 | - | Extra Bolagsstämma 2022 |
| 2022-11-18 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-30 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-27 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-26 | - | X-dag ordinarie utdelning CMH 0.00 SEK |
| 2022-04-25 | - | Årsstämma |
| 2022-02-25 | - | Bokslutskommuniké 2021 |
| 2021-10-25 | - | Kvartalsrapport 2021-Q3 |
| 2021-10-05 | - | Extra Bolagsstämma 2021 |
| 2021-08-30 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-27 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-16 | - | X-dag ordinarie utdelning CMH 0.00 SEK |
| 2021-04-15 | - | Årsstämma |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-11-20 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-18 | - | Extra Bolagsstämma 2020 |
| 2020-08-07 | - | Kvartalsrapport 2020-Q2 |
| 2020-04-29 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-24 | - | X-dag ordinarie utdelning CMH 0.00 SEK |
| 2020-04-23 | - | Årsstämma |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-11 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-30 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-24 | - | Kvartalsrapport 2019-Q1 |
| 2019-05-10 | - | X-dag ordinarie utdelning CMH 0.00 SEK |
| 2019-05-09 | - | Årsstämma |
| 2019-02-28 | - | Bokslutskommuniké 2018 |
| 2018-11-16 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-31 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-25 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-27 | - | X-dag ordinarie utdelning CMH 0.00 SEK |
| 2018-04-26 | - | Årsstämma |
| 2018-02-28 | - | Bokslutskommuniké 2017 |
| 2017-10-31 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-31 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-28 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-20 | - | X-dag ordinarie utdelning CMH 0.00 SEK |
| 2017-04-19 | - | Årsstämma |
| 2017-02-10 | - | Bokslutskommuniké 2016 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Chordate Medical Holding AB announces that the United States Patent and Trademark Office (USPTO) has decided to grant registration of Chordate’s trademark OZILIA.
This marks the fifth national registration of OZILIA under the Madrid Protocol, meaning that the trademark is now registered in the U.S., Israel, Japan, China, and the United Kingdom. A corresponding application for registration in Brazil is currently under review. Since 2023, the trademark has also been registered in the European Union.
“The OZILIA trademark has been well received by the market, and protecting it through registrations is part of our IP strategy aimed at building long-term value in the company and making the business more attractive to potential buyers,” says Anders Weilandt, CEO of Chordate Medical.
For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277
About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com
The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.
N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.